# EDGAR Filing Document

**Accession Number:** 0001845459
**File Stem:** 0001104659-25-055326
**Filing Date:** 2025-6
**Character Count:** 16707
**Document Hash:** 243a1e9a905e62b4a38f988ca3101675
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-055326.hdr.sgml**: 20250602

**ACCESSION NUMBER**: 0001104659-25-055326

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250602

**DATE AS OF CHANGE**: 20250602

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NKGen Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001845459
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92576
- **FILM NUMBER:** 251013804

**BUSINESS ADDRESS:**
- **STREET 1:** 3001 DAIMLER ST,
- **CITY:** SANTA ANA
- **STATE:** CA
- **ZIP:** 92705
- **BUSINESS PHONE:** (949) 396-6830

**MAIL ADDRESS:**
- **STREET 1:** 3001 DAIMLER ST,
- **CITY:** SANTA ANA
- **STATE:** CA
- **ZIP:** 92705

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Graf Acquisition Corp. IV
- **DATE OF NAME CHANGE:** 20210210
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CFIC-2015 NV Family Investments, LLC
- **CENTRAL INDEX KEY:** 0002034776

**ORGANIZATION NAME:**
- **EIN:** 475267544
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 1120 N. TOWN CENTER DRIVE
- **STREET 2:** SUITE 150
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89144
- **BUSINESS PHONE:** 626-799-9898

**MAIL ADDRESS:**
- **STREET 1:** 1120 N. TOWN CENTER DRIVE
- **STREET 2:** SUITE 150
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89144

## Ex-99.A

**Exhibit A**

**Joint Filing Agreement** 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the entity and persons named below (i) agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto, the "***Schedule 13D***") with respect to the common stock, $0.0001 par value per share of NKGen Biotech, Inc., (ii) agree that each party hereto is responsible for the timely filing of the Schedule 13D, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has a reason to believe that such information is inaccurate, and (iii) agree that this Joint Filing Agreement be included as an exhibit to the Schedule 13D.

**IN WITNESS WHEREOF**, the undersigned hereby execute this Joint Filing Agreement as of May 29, 2025.

---

| | |
|:---|:---|
| **CFIC-2015 NV Family Investments, LLC** | **CFIC-2015 NV Family Investments, LLC** |
| By: | /s/ Mecky Wong |
| Name: | Mecky Wong |
| Title: | Manager |

---

---

| | |
|:---|:---|
| By: | /s/ Andrew Cherng |
| Name: | Andrew Cherng |

---

---

| | |
|:---|:---|
| By: | /s/ Peggy Cherng |
| Name: | Peggy Cherng |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**NKGen Biotech, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**65488A101**

*(CUSIP Number)*

**Will Mak**<br>1120 N. Town Center Drive, Suite 150<br>Las Vegas NV 89144<br>949-872-0737

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**05/27/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **65488A101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**CFIC-2015 NV Family Investments, LLC** | Name of reporting person<br>**CFIC-2015 NV Family Investments, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**NEVADA** | Citizenship or place of organization<br>**NEVADA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**63175321.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**63175321.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**63175321.00** | Aggregate amount beneficially owned by each reporting person<br>**63175321.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**47.2%** | Percent of class represented by amount in Row (11)<br>**47.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The aggregate amount of shares beneficially owned (63,175,321) consists of (a) 2,083,333 shares of common stock, $0.0001 par value per share (the "Common Stock") of NKGen Biotech, Inc. (the "Issuer") issued pursuant to the 2024 Purchase Agreement (as defined in Item 6 below), (b) CFIC-2015 NV Family Investments, LLC's right to acquire 2,083,333 additional shares of Common Stock pursuant to the 2024 Letter Agreement (as defined in Item 6 below), (c) 19,669,552 shares of Common Stock of the Issuer issued pursuant to the 2025 Purchase Agreement (as defined in Item 3 below), and (d) CFIC-2015 NV Family Investments, LLC's right to acquire 39,339,103 shares of Common Stock pursuant to the 2025 Warrant (as defined in Item 3 below).

The percent of class in row 13 is based on 74,750,212 shares of Common Stock outstanding as of May 9, 2025, as represented by the Issuer in the 2025 Purchase Agreement, plus the 59,008,655 shares of Common Stock beneficially owned by the reporting person pursuant to the 2025 Purchase Agreement and the 2025 Warrant.

| **CUSIP No.** | **65488A101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Andrew Jin-Chan Cherng** | Name of reporting person<br>**Andrew Jin-Chan Cherng** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**63175321.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**63175321.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**63175321.00** | Aggregate amount beneficially owned by each reporting person<br>**63175321.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**47.2%** | Percent of class represented by amount in Row (11)<br>**47.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Andrew Cherng and Peggy Cherng together own 100% of the voting interests of CFIC-2015 NV Family Investments, LLC.

The aggregate amount of shares beneficially owned (63,175,321) consists of (a) 2,083,333 shares of Common Stock issued pursuant to the 2024 Purchase Agreement (as defined in Item 6 below), (b) CFIC-2015 NV Family Investments, LLC's right to acquire 2,083,333 additional shares of Common Stock pursuant to the 2024 Letter Agreement (as defined in Item 6 below), (c) 19,669,552 shares of Common Stock of the Issuer issued pursuant to the 2025 Purchase Agreement (as defined in Item 3 below), and (d) CFIC-2015 NV Family Investments, LLC's right to acquire 39,339,103 shares of Common Stock pursuant to the 2025 Warrant (as defined in Item 3 below).

The percent of class in row 13 is based on 74,750,212 shares of Common Stock outstanding as of May 9, 2025, as represented by the Issuer in the 2025 Purchase Agreement, plus the 59,008,655 shares of Common Stock beneficially owned by the reporting person pursuant to the 2025 Purchase Agreement and the 2025 Warrant.

| **CUSIP No.** | **65488A101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Peggy Cherng** | Name of reporting person<br>**Peggy Cherng** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**63175321.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**63175321.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**63175321.00** | Aggregate amount beneficially owned by each reporting person<br>**63175321.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**47.2%** | Percent of class represented by amount in Row (11)<br>**47.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Andrew Cherng and Peggy Cherng together own 100% of the voting interests of CFIC-2015 NV Family Investments, LLC.

The aggregate amount of shares beneficially owned (63,175,321) consists of (a) 2,083,333 shares of Common Stock issued pursuant to the 2024 Purchase Agreement (as defined in Item 6 below), (b) CFIC-2015 NV Family Investments, LLC's right to acquire 2,083,333 additional shares of Common Stock pursuant to the 2024 Letter Agreement (as defined in Item 6 below), (c) 19,669,552 shares of Common Stock of the Issuer issued pursuant to the 2025 Purchase Agreement (as defined in Item 3 below), and (d) CFIC-2015 NV Family Investments, LLC's right to acquire 39,339,103 shares of Common Stock pursuant to the 2025 Warrant (as defined in Item 3 below).

The percent of class in row 13 is based on 74,750,212 shares of Common Stock outstanding as of May 9, 2025, as represented by the Issuer in the 2025 Purchase Agreement, plus the 59,008,655 shares of Common Stock beneficially owned by the reporting person pursuant to the 2025 Purchase Agreement and the 2025 Warrant.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
NKGen Biotech, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
3001 Daimler Street, Santa Ana, CA, 92705

**Item 4. Purpose of Transaction**

The securities were acquired for investment purposes. From time to time, the Reporting Persons and their affiliates may engage in discussions with management, the board of directors (the "Board"), and stockholders of the Issuer and other relevant parties regarding business practices and governance policies of the Company. The Reporting Persons intend to monitor the performance and corporate governance of the Company, as well as the actions of the Company's management and Board and will assert stockholder rights as deemed necessary. Other than as described in this paragraph, the Reporting Persons have no present plans or proposals that relate to or would result in any of the actions enumerated in Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See responses to Items 11 and 13 of the Cover Page for each Reporting Person.

**(b)**
See responses to Items 7 through 10 of the Cover Page for each Reporting Person.

**(c)**
None.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

See response to Item 3 above.

As previously reported on a Schedule 13G filed on August 22, 2024, on August 12, 2024, pursuant to a Securities Purchase Agreement dated as of August 7, 2024 (the "2024 Purchase Agreement") by and between CFIC-2015 and the Issuer, which was filed as Exhibit 10.2 to the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 9, 2024, the Issuer issued to CFIC-2015 2,083,333 shares of Common Stock as Commitment Shares (as defined in the 2024 Purchase Agreement). Pursuant to the 2024 Purchase Agreement, CFIC-2015 also purchased a convertible promissory note (the "2024 Note") and received a warrant to purchase shares of Common Stock (the "2024 Warrant"). On August 7, 2024, the Issuer entered into a letter agreement with CFIC-2015 (the "2024 Letter Agreement"), which was filed as Exhibit 10.3 to the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 9, 2024, pursuant to which CFIC-2015 has the right to acquire up to 2,083,333 shares of Common Stock as commitment shares (the "Additional Shares") upon the purchase by CFIC-2015 of up to an aggregate principal amount of $2,750,000 of convertible promissory notes (the "Additional Note") from the Issuer. Pursuant to the Letter Agreement, if acquired, the Additional Shares will be issued upon the terms and conditions set forth in the 2024 Purchase Agreement. Upon purchase of the Additional Note, CFIC-2015 would also receive additional warrants to purchase shares of Common Stock.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** CFIC-2015 NV Family Investments, LLC

**Signature:** /s/ Mecky Wong

**Name/Title:** Mecky Wong/Manager

**Date:** 05/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Andrew Jin-Chan Cherng

**Signature:** /s/ Andrew Cherng

**Name/Title:** Andrew Cherng

**Date:** 05/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Peggy Cherng

**Signature:** /s/ Peggy Cherng

**Name/Title:** Peggy Cherng

**Date:** 05/29/2025